BlackRock Inc. lowered its position in Catalent Inc (NYSE:CTLT) by 5.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,721,278 shares of the company’s stock after selling 913,689 shares during the quarter. BlackRock Inc. owned approximately 0.13% of Catalent worth $686,910,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in CTLT. Stifel Financial Corp lifted its stake in Catalent by 0.9% in the second quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock valued at $377,000 after acquiring an additional 96 shares during the last quarter. Royal Bank of Canada lifted its stake in Catalent by 46.7% in the second quarter. Royal Bank of Canada now owns 35,029 shares of the company’s stock valued at $1,230,000 after acquiring an additional 11,151 shares during the last quarter. Oakbrook Investments LLC acquired a new stake in Catalent in the third quarter valued at $343,000. Nationwide Fund Advisors lifted its stake in Catalent by 18.4% in the third quarter. Nationwide Fund Advisors now owns 382,620 shares of the company’s stock valued at $15,274,000 after acquiring an additional 59,528 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in Catalent by 1.5% in the third quarter. First Trust Advisors LP now owns 109,815 shares of the company’s stock valued at $4,384,000 after acquiring an additional 1,597 shares during the last quarter. Hedge funds and other institutional investors own 99.82% of the company’s stock.
Shares of Catalent Inc (NYSE CTLT) opened at $42.84 on Monday. The company has a debt-to-equity ratio of 2.66, a quick ratio of 1.78 and a current ratio of 2.22. The stock has a market cap of $5,711.39, a PE ratio of 75.16, a PEG ratio of 2.46 and a beta of 1.47. Catalent Inc has a 12 month low of $27.48 and a 12 month high of $47.87.
A number of analysts have commented on the stock. Zacks Investment Research cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Bank of America increased their price target on shares of Catalent from $47.00 to $49.00 and gave the company a “buy” rating in a research note on Tuesday, February 6th. Stephens cut shares of Catalent from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, February 6th. Finally, Royal Bank of Canada set a $48.00 price target on shares of Catalent and gave the company a “buy” rating in a research note on Monday, February 5th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Catalent currently has an average rating of “Buy” and an average target price of $45.70.
In other news, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total transaction of $7,189,365.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Catalent Inc (CTLT) Holdings Reduced by BlackRock Inc.” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3222618/catalent-inc-ctlt-holdings-reduced-by-blackrock-inc.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.